Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    Open Access Initiative Helps Neglected Tropical Disease Drug Effort

    By Global Biodefense StaffNovember 13, 2012
    Share
    Facebook LinkedIn Reddit Email

    The potential of openly sharing drug development data for neglected or rare diseases was aptly demonstrated with this week’s announcement of the identification of three promising compounds targeting the treatment of trypanosomiasis and leishmaniasis. 

    The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce the findings today, obtained through DNDi’s screening of MMV’s open access Malaria Box. 

    The Malaria Box is an MMV initiative launched in late 2011 which provides researchers with a collection of 400 diverse compounds with antimalarial activity with the aim of catalyzing malaria and neglected disease drug discovery and research. All of the compounds have confirmed activity against the blood-stage of P. falciparum and are commercially available.  All that is asked in return of Malaria Box users is for the resulting data to be published and placed in the public domain to help continue the cycle of research. 

    DNDi, in partnership with the University of Antwerp Laboratory for Microbiology, Parasitology and Hygiene, screened all the compounds in the Malaria Box against the parasites responsible for the three tropical diseases on which DNDi mainly focuses: human African trypanosomiasis (sleeping sickness), leishmaniasis, and Chagas disease. 

    The screen identified two potential drug series for the treatment of sleeping sickness and one for leishmaniasis and has yielded valuable information that will strengthen DNDi’s research pipeline. All the biological data from DNDi’s screen are now available and are among the first generated from the Malaria Box to be released into the public domain. 

    “This is a really great example of partnership in action,” said Dr David Reddy, MMV’s CEO. “MMV and DNDi already work synergistically to tackle tropical diseases. Now, through the Malaria Box we can freely explore molecules that could potentially work against several debilitating tropical diseases, for the benefit of vulnerable populations the world over. It’s hugely gratifying to see the idea of the Malaria Box starting to pay off.” 

    To date, more than 100 Malaria Boxes have been delivered to over 20 countries for research on diseases including malaria, neglected diseases, HIV and cancer. 

    Visit website: Drugs for Neglected Diseases initiative (DNDi)
    Visit website: Medicines for Malaria Venture (MMV)
     
    Chagas Human African Trypanosomiasis Leishmaniasis Malaria Neglected Tropical Diseases
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleNIH, CDC Small Business Innovation for Medical Countermeasures
    Next Article Homeland Security Essay Competition

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Case Study: Fatal Avian Influenza Infection in Cat in Poland

    September 15, 2023

    Bird Flu Undergoing Changes That Could Increase Risk of Widespread Human Transmission

    September 14, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy